genOway Société anonyme (ALGEN.PA)
EUR 3.92
(0.0%)
EUR 3.92
(0.0%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 20.04 Million EUR | 17.55% |
| 2022 | 17.05 Million EUR | 21.64% |
| 2021 | 14.01 Million EUR | 27.26% |
| 2020 | 11.01 Million EUR | -22.85% |
| 2019 | 14.27 Million EUR | -4.51% |
| 2018 | 14.95 Million EUR | 13.59% |
| 2017 | 13.16 Million EUR | 14.09% |
| 2016 | 11.53 Million EUR | 13.89% |
| 2015 | 10.13 Million EUR | 5.16% |
| 2014 | 9.63 Million EUR | -2.15% |
| 2013 | 9.84 Million EUR | 12.68% |
| 2012 | 8.73 Million EUR | 12.87% |
| 2011 | 7.74 Million EUR | 5.41% |
| 2010 | 7.34 Million EUR | 11.04% |
| 2009 | 6.61 Million EUR | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 10.71 Million EUR | 0.0% |
| 2023 FY | 20.04 Million EUR | 17.55% |
| 2023 Q2 | 9.33 Million EUR | 0.0% |
| 2023 Q4 | 10.71 Million EUR | 0.0% |
| 2022 FY | 17.05 Million EUR | 21.64% |
| 2022 Q4 | 9.29 Million EUR | 0.0% |
| 2022 Q2 | 7.75 Million EUR | 0.0% |
| 2021 Q4 | 7.83 Million EUR | 0.0% |
| 2021 FY | 14.01 Million EUR | 27.26% |
| 2021 Q2 | 6.18 Million EUR | 0.0% |
| 2020 Q2 | 4.75 Million EUR | 0.0% |
| 2020 Q4 | 6.26 Million EUR | 0.0% |
| 2020 FY | 11.01 Million EUR | -22.85% |
| 2019 Q2 | 6.31 Million EUR | 0.0% |
| 2019 Q4 | 5.44 Million EUR | 0.0% |
| 2019 FY | 14.27 Million EUR | -4.51% |
| 2018 Q2 | 6.61 Million EUR | 0.0% |
| 2018 FY | 14.95 Million EUR | 13.59% |
| 2018 Q4 | 8.33 Million EUR | 0.0% |
| 2017 Q2 | 6.59 Million EUR | 0.0% |
| 2017 FY | 13.16 Million EUR | 14.09% |
| 2017 Q4 | 6.13 Million EUR | 0.0% |
| 2016 Q4 | 6.27 Million EUR | 0.0% |
| 2016 Q2 | 5.26 Million EUR | 0.0% |
| 2016 FY | 11.53 Million EUR | 13.89% |
| 2015 Q2 | 5.11 Million EUR | 0.0% |
| 2015 Q4 | 5.01 Million EUR | 0.0% |
| 2015 FY | 10.13 Million EUR | 5.16% |
| 2014 Q4 | 4.84 Million EUR | 0.0% |
| 2014 FY | 9.63 Million EUR | -2.15% |
| 2014 Q2 | 4.79 Million EUR | 0.0% |
| 2013 Q2 | 4.98 Million EUR | 0.0% |
| 2013 Q4 | 4.85 Million EUR | 0.0% |
| 2013 FY | 9.84 Million EUR | 12.68% |
| 2012 Q3 | 1.85 Million EUR | 0.0% |
| 2012 Q1 | 1.85 Million EUR | 0.0% |
| 2012 Q4 | 1.92 Million EUR | 3.99% |
| 2012 FY | 8.73 Million EUR | 12.87% |
| 2012 Q2 | 1.85 Million EUR | 0.0% |
| 2011 Q3 | 1.93 Million EUR | 0.0% |
| 2011 FY | 7.74 Million EUR | 5.41% |
| 2011 Q4 | 1.85 Million EUR | -4.37% |
| 2011 Q2 | 1.93 Million EUR | 0.0% |
| 2011 Q1 | 1.93 Million EUR | 0.0% |
| 2010 Q1 | 1.83 Million EUR | 0.0% |
| 2010 Q4 | 1.93 Million EUR | 5.41% |
| 2010 FY | 7.34 Million EUR | 11.04% |
| 2010 Q3 | 1.83 Million EUR | 0.0% |
| 2010 Q2 | 1.83 Million EUR | 0.0% |
| 2009 FY | 6.61 Million EUR | 0.0% |
| 2009 Q1 | 1.65 Million EUR | 0.0% |
| 2009 Q4 | 1.83 Million EUR | 11.04% |
| 2009 Q3 | 1.65 Million EUR | 0.0% |
| 2009 Q2 | 1.65 Million EUR | 0.0% |
| 2008 Q4 | 1.65 Million EUR | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| ABIONYX Pharma SA | 4.64 Million EUR | -332.034% |
| ABIVAX Société Anonyme | 4.62 Million EUR | -333.81% |
| Adocia SA | 2.15 Million EUR | -832.39% |
| Aelis Farma SA | 9.05 Million EUR | -121.409% |
| Biophytis S.A. | - EUR | -Infinity% |
| Advicenne S.A. | 3.15 Million EUR | -536.191% |
| IntegraGen SA | 12.53 Million EUR | -59.892% |
| Medesis Pharma S.A. | 300.03 Thousand EUR | -6581.37% |
| Neovacs S.A. | 533.41 Thousand EUR | -3658.142% |
| NFL Biosciences SA | - EUR | -Infinity% |
| Plant Advanced Technologies SA | 1.68 Million EUR | -1092.162% |
| Quantum Genomics Société Anonyme | 19.79 Thousand EUR | -101164.811% |
| Sensorion SA | 4.74 Million EUR | -322.646% |
| Theranexus Société Anonyme | 296.33 Thousand EUR | -6664.862% |
| TME Pharma N.V. | 17 Thousand EUR | -117819.894% |
| Valbiotis SA | 4.73 Million EUR | -323.545% |
| TheraVet SA | 1.07 Million EUR | -1759.495% |
| Valerio Therapeutics Société anonyme | 1.8 Million EUR | -1013.688% |
| argenx SE | 1.13 Billion EUR | 98.233% |
| BioSenic S.A. | 543 Thousand EUR | -3591.783% |
| Celyad Oncology SA | 102 Thousand EUR | -19553.316% |
| DBV Technologies S.A. | - EUR | -Infinity% |
| Galapagos NV | 239.72 Million EUR | 91.638% |
| Genfit S.A. | 28.56 Million EUR | 29.822% |
| GeNeuro SA | - EUR | -Infinity% |
| Hyloris Pharmaceuticals SA | 2.08 Million EUR | -860.536% |
| Innate Pharma S.A. | 51.9 Million EUR | 61.376% |
| Inventiva S.A. | 17.47 Million EUR | -14.702% |
| MaaT Pharma SA | 2.22 Million EUR | -799.748% |
| MedinCell S.A. | 9.16 Million EUR | -118.847% |
| Nanobiotix S.A. | 30.05 Million EUR | 33.308% |
| Onward Medical N.V. | 532 Thousand EUR | -3668.117% |
| Oryzon Genomics S.A. | 14.19 Million EUR | -41.255% |
| OSE Immunotherapeutics SA | 2.22 Million EUR | -800.152% |
| Oxurion NV | 263 Thousand EUR | -7522.198% |
| Pharming Group N.V. | 245.31 Million EUR | 91.828% |
| Poxel S.A. | 1.98 Million EUR | -911.932% |
| GenSight Biologics S.A. | 1.26 Million EUR | -1482.193% |
| Transgene SA | 1.18 Million EUR | -1593.107% |
| Financière de Tubize SA | - EUR | -Infinity% |
| UCB SA | 5.25 Billion EUR | 99.618% |
| Valneva SE | 153.71 Million EUR | 86.958% |
| Vivoryon Therapeutics N.V. | -3.62 Million EUR | 653.767% |